CHRISTINE DAVIDSON: Open Payments
NPI 1801265368 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,376 in 46 payments from 10 companies in 2025. Trend: 2023 $157 · 2024 $271 · 2025 $1,376
Food & beverage: $1,376
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $321 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $301 |
| Braeburn Inc. | 7 | $217 |
| Otsuka America Pharmaceutical, Inc. | 6 | $210 |
| Neurocrine BioSciences, Inc. | 2 | $134 |
| Lundbeck LLC | 3 | $59 |
| Indivior Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Almatica Pharma LLC | 1 | $28 |
| Bausch Health US, LLC | 1 | $23 |
Products named: CAPLYTA, REXULTI, VRAYLAR, BRIXADI, INGREZZA, MAVYRET, SUBLOCADE, TRINTELLIX.
Industry payments across MD — which companies pay providers there.
